Past CureTalks
Understanding ASCENT Clinical Trial for High Risk Smoldering Myeloma Patients
This is the first of a 3 part series of talk on high risk smoldering myeloma and its treatments. Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder. There have been major advances in the diagnosis, prognosis, and…
Family Building Using Assisted Reproductive Techniques (ART) : Legal Aspects
A modern couple has various options to build their family at their choice of time with the advent of ground breaking reproductive technologies made available by our scientific fraternity. For either medical or non medical reasons, more and more couples…
Preventing Relapse in Multiple Myeloma
Recent introduction of new therapies has significantly improved outcomes for patients diagnosed with multiple myeloma. However, cures remain rare in myeloma and most people may eventually relapse. If we can better understand how and why myeloma grows back, there is…
What is Value for Patients in the Management of Prostate Cancer.
At all stages of and levels of prostate cancer, whether you have low, intermediate, or high risk disease, whether you are newly diagnosed, have recurrent disease or your prostate cancer has advanced and metastasized, the same questions arise. What is…
What you need to know about the ICER report and its implication on insurance coverage and treatment options for myeloma patients.
Cancer drugs cost more than $100,000 per year and continue to increase. Medicare has proposed major changes to Medicare Part B in an attempt to slow the explosion in healthcare expenditures. In addition, a recent “report” by a group called…